Sean Studer
YOU?
Author Swipe
View article: Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart Disease
Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart Disease Open
Treatment with approved PAH drugs provided a similar reduction in M/M risk in patients with repaired CHD-PAH when compared with the overall PAH population. This pooled analysis provides important evidence to guide medical management in thi…
View article: Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis
Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis Open
This real‐world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Co…
View article: The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network
The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network Open
Background. Portopulmonary hypertension (PoPH) occurs in patients with advanced liver disease and can be a contraindication to liver transplant (LT). Improvement of hemodynamic parameters with pulmonary arterial hypertension (PAH) therapie…
View article: Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study
Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study Open
Regular expert follow‐up, risk assessment, and early therapeutic intervention minimize worsening of pulmonary arterial hypertension (PAH). COVID‐19 lockdown measures were challenging for chronic disease management. This retrospective, long…
View article: Small sequence variations between two mammalian paralogs of the small GTPase SAR1 underlie functional differences in coat protein complex II assembly
Small sequence variations between two mammalian paralogs of the small GTPase SAR1 underlie functional differences in coat protein complex II assembly Open
View article: SAR1 paralogs differ biochemically in assembly of the COPII coat
SAR1 paralogs differ biochemically in assembly of the COPII coat Open
COPII-coated vesicles are the primary mediators of vesicular traffic from the ER to the Golgi apparatus. SAR1 is a small GTPase, which, upon GTP binding, recruits the other COPII proteins to the ER membrane. In mammals, there are two SAR1 …
View article: Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension
Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension Open
View article: Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex
Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex Open
Dimethyl fumarate (DMF) is a prescribed treatment for multiple sclerosis and has also been used to treat psoriasis. The electrophilicity of DMF suggests that its immunosuppressive activity is related to the covalent modification of cystein…
View article: Ask the Expert: Transplantation in Eisenmenger Syndrome: Getting to the Heart of the Matter
Ask the Expert: Transplantation in Eisenmenger Syndrome: Getting to the Heart of the Matter Open
Pulmonary hypertension (PH) is a common complication of congenital heart disease (CHD), often developing as a result of vascular remodeling from long-standing left-to-right shunting and pulmonary overcirculation. The most severe form of CH…
View article: Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real‐world US database
Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real‐world US database Open
Several new medications for pulmonary arterial hypertension (PAH) have recently been introduced; however, current real‐world data regarding US patients with PAH are limited. We conducted a retrospective administrative claims study to exami…
View article: Ask the Expert: What Is the Association Between Thyroid Disease and Pulmonary Hypertension: Do Pulmonary Arterial Hypertension Patients Need a Closer Look?
Ask the Expert: What Is the Association Between Thyroid Disease and Pulmonary Hypertension: Do Pulmonary Arterial Hypertension Patients Need a Closer Look? Open
Thyroid hormone exerts numerous effects on the cardiovascular system through a number of mechanisms including direct effects on the heart and via interactions with the autonomic nervous system, vascular bed, and endothelium.1 A wealth of o…
View article: Might Rebranding Palliative Care Improve its Integration into Treatment for Those Patients Diagnosed With Pulmonary Arterial Hypertension?
Might Rebranding Palliative Care Improve its Integration into Treatment for Those Patients Diagnosed With Pulmonary Arterial Hypertension? Open
The original name of the Patagonian toothfish, Dissostichus eleginoides, did not likely inspire many fantasies of fine dining until it was renamed the Chilean sea bass in 1977 by a fisherman named Lee Lantz. That this fish is not a bass at…
View article: Ask the Expert: How Can I Best Provide Care to My Incarcerated Patient With Pulmonary Hypertension?
Ask the Expert: How Can I Best Provide Care to My Incarcerated Patient With Pulmonary Hypertension? Open
From a strictly legal standpoint, once incarcerated, your patient is no longer your patient, but that of the health system legally obligated to provide health care to that person. For physicians who have worked in an occupational medicine …
View article: Ask The Expert
Ask The Expert Open
Raynaud's phenomenon (RP) is the most common complication of scleroderma (SSc), affecting over 95% of patients with this disease.1 Raynaud's phenomenon results from structural and functional abnormalities in the digital arteries and is cha…
View article: Ask The Expert: What Are Some Pitfalls and Promises of the Current PAH Treatment Guidelines?
Ask The Expert: What Are Some Pitfalls and Promises of the Current PAH Treatment Guidelines? Open
Medical therapies for the treatment of pulmonary arterial hypertension (PAH) have evolved rapidly over the last 2 decades. From December 1995 to December 2015, 11 different drugs have been approved for treatment of PAH in the United States…
View article: S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification
S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification Open
Significance The sphingosine 1-phosphate receptor (S1PR1) is known to act by multiple mechanisms: limiting lymphocyte egress from secondary lymphoid organs, suppressing proinflammatory endothelial cell function, and acting directly on neur…
View article: Ask the Expert: Is Cardiac Magnetic Resonance Imaging Underutilized in the Diagnosis of Pulmonary Hypertension?
Ask the Expert: Is Cardiac Magnetic Resonance Imaging Underutilized in the Diagnosis of Pulmonary Hypertension? Open
Cardiac magnetic resonance imaging (CMR) provides an important and complementary role to conventional imaging in the evaluation of patients with pulmonary hypertension (PH). Echocardiography remains vital given its ability to quickly asses…
View article: Ask the Expert: Management of Right Ventricular Failure in Acute Pulmonary Embolism
Ask the Expert: Management of Right Ventricular Failure in Acute Pulmonary Embolism Open
The management of acute right ventricular (RV) failure in acute pulmonary embolism (PE) differs from RV failure in chronic forms of pulmonary hypertension (PH) such as pulmonary arterial hypertension (PAH). In PE, RV failure generally occu…
View article: Ask the Expert: What Is the Utility of Evaluating Patients for Exercise-Induced Pulmonary Hypertension?
Ask the Expert: What Is the Utility of Evaluating Patients for Exercise-Induced Pulmonary Hypertension? Open
Pulmonary hypertension (PH) is currently defined by a resting mean pulmonary artery pressure (mPAP) that is ≥25 mm Hg.1 Prior to 2009, the definition of PH also included those with mPAP ≥30 mm Hg with exercise, while the diagnosis of exerc…